 The U.S. Food and Drug Administration FDA has granted Fast Track Designation to Midatech Pharma PLCs NASDAQ: MTP lead drug candidate MTX110 for the treatment of patients with recurrent glioblastoma rGBM. The company is planning to begin recruitment in the phase 1 study evaluating MTX110. 